Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis
Standard
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis. / Reich, Kristian; Baraliakos, Xenophon; Coates, Laura C; Elewski, Boni; Bao, Weibin; Kasparek, Torben; Gaillez, Corine; Pournara, Effie; Aassi, Maher; Perella, Chiara; Gottlieb, Alice B.
in: BRIT J DERMATOL, Jahrgang 187, Nr. 3, 09.2022, S. 438-441.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis
AU - Reich, Kristian
AU - Baraliakos, Xenophon
AU - Coates, Laura C
AU - Elewski, Boni
AU - Bao, Weibin
AU - Kasparek, Torben
AU - Gaillez, Corine
AU - Pournara, Effie
AU - Aassi, Maher
AU - Perella, Chiara
AU - Gottlieb, Alice B
N1 - © 2022 British Association of Dermatologists.
PY - 2022/9
Y1 - 2022/9
N2 - Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.
AB - Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.
KW - Antibodies, Monoclonal, Humanized
KW - Arthritis, Psoriatic/complications
KW - Humans
KW - Nail Diseases/complications
KW - Nails, Malformed
KW - Psoriasis/complications
KW - Severity of Illness Index
U2 - 10.1111/bjd.21233
DO - 10.1111/bjd.21233
M3 - Other (editorial matter etc.)
C2 - 35257363
VL - 187
SP - 438
EP - 441
JO - BRIT J DERMATOL
JF - BRIT J DERMATOL
SN - 0007-0963
IS - 3
ER -